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ARTICLE
TRPA1–FGFR2 binding event is a regulatory
oncogenic driver modulated by miRNA-142-3p
Jonathan Berrout1, Eleni Kyriakopoulou 1, Lavanya Moparthi2, Alexandra S. Hogea3, Liza Berrout4,
Cristina Ivan 5, Mihaela Lorger6, John Boyle 7, Chris Peers7, Stephen Muench 3, Jacobo Elies Gomez 7,
Xin Hu8, Carolyn Hurst9, Thomas Hall1, Sujanitha Umamaheswaran10, Laura Wesley1, Mihai Gagea 11,
Michael Shires 12, Iain Manﬁeld1, Margaret A. Knowles 9, Simon Davies3, Klaus Suhling13,
Yurema Teijeiro Gonzalez13, Neil Carragher14, Kenneth Macleod14, N. Joan Abbott15, George A. Calin16,
Nikita Gamper 3, Peter M. Zygmunt2 & Zahra Timsah1
Recent evidence suggests that the ion channel TRPA1 is implicated in lung adenocarcinoma
(LUAD), where its role and mechanism of action remain unknown. We have previously
established that the membrane receptor FGFR2 drives LUAD progression through aberrant
protein–protein interactions mediated via its C-terminal proline-rich motif. Here we report
that the N-terminal ankyrin repeats of TRPA1 directly bind to the C-terminal proline-rich motif
of FGFR2 inducing the constitutive activation of the receptor, thereby prompting LUAD
progression and metastasis. Furthermore, we show that upon metastasis to the brain, TRPA1
gets depleted, an effect triggered by the transfer of TRPA1-targeting exosomal microRNA
(miRNA-142-3p) from brain astrocytes to cancer cells. This downregulation, in turn, inhibits
TRPA1-mediated activation of FGFR2, hindering the metastatic process. Our study reveals a
direct binding event and characterizes the role of TRPA1 ankyrin repeats in regulating FGFR2-
driven oncogenic process; a mechanism that is hindered by miRNA-142-3p.
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Lung cancer is the leading cause of cancer-related mortalityand the second most common type of cancer worldwide1.Lung adenocarcinoma (LUAD) accounts for 40% of all lung
cancer cases; it often metastasizes to the liver, adrenal glands,
bones, and brain2, 3. Notably, ~50% of all cases of brain metas-
tases originate from lung cancer, where early metastatic spread to
the brain is hard to detect, and thus long-term survival of patients
is very rare4–6. The role of the brain metastatic niche in regulating
tumor progression remains controversial. Some studies have
shown that brain astrocytes support the survival of cancer cells in
a dormant state, by inhibiting further proliferation and invasion,
while others describe a mechanism that supports the metastatic
process7, 8.
Recently, it has been reported that the ion channel, transient
receptor potential ankyrin-1 (TRPA1), which is expressed in
nociceptive neurons and acts as a chemosensor of noxious
compounds, is implicated in lung malignancies9–12. While
TRPA1 has been shown to be expressed in non-neuronal cells as
well (e.g., lung epithelial ﬁbroblasts), little is known about its
function outside the somatosensory system, even less in malig-
nancies11–13. TRPA1 possesses an extended C-terminal domain,
which is important for subunit interactions during channel
assembly. Its N-terminal region contains 16 ankyrin repeats with
a putative, yet uncharacterized, role in pore-gating and mediating
protein–protein interactions, where the binding partners are yet-
to-be identiﬁed11, 14. Interestingly, a regulatory protein–protein
interaction has been reported to occur between the ankyrin
repeats of ANKRA protein and the proline-rich cytoplasmic
domain of megalin receptor15. This prompted us to investigate
the regulatory role of TRPA1 ankyrin repeats in LUAD.
In lung malignancies, and speciﬁcally LUAD, we have pre-
viously shown that the membrane receptor, ﬁbroblast growth
factor receptor 2 (FGFR2), is a critical driver of disease pro-
gression, especially under non-stimulated conditions16–19. In this
case, FGFR2 recruits proteins to its C-terminal proline-rich motif
to trigger signaling cascades and aberrant cellular functions
independent of extracellular stimulation17.
All of the above urged us to investigate the potential interaction
between TRPA1 and FGFR2 in LUAD. In the present study, we
reveal a direct binding event between ankyrins 6–10 of TRPA1
and prolines 810–813 of FGFR2, which constitutively activates
the receptor and its signaling pathways independent of extra-
cellular stimulation. TRPA1-FGFR2 supports the oncogenic
process in LUAD and its metastasis to the brain. Our study also
uncovers that upon encounter with astrocytes in the brain, LUAD
cells are depleted of TRPA1, which inhibits FGFR2- driven cel-
lular proliferation and invasion. We demonstrate that this occurs
by the transfer of TRPA1-targeting exosomal miRNA-142-3p
from astrocytes to LUAD (as illustrated in Supplementary Fig. 1).
Results
C-terminal region of FGFR2 binds to TRPA1 ankyrin repeats.
We assessed the expression level of both the proteins in LUAD by
performing an immunohistochemical (IHC) analysis of a tissue
microarray containing 102 normal and lung cancer tissue samples
(Fig. 1a, b). Unlike in normal tissues, it is evident that both the
proteins are highly expressed in LUAD samples with a patholo-
gical score of 3+ in 60–70% of the cancer tissues investigated
(Fig. 1b). Compared to normal tissues (as shown in the zoomed-
in yellow boxes), neoplastic epithelial cells in LUAD samples
stained strongly positive for FGFR2 (red arrow). Most of the
stroma is negative for FGFR2 staining, but the inﬂammatory cells
inﬁltrated into the stroma have positive FGFR2 staining (green
arrow). For TRPA1, there is a strong positive staining of the
neoplastic epithelial cells (red arrows). The supporting stroma
(ﬁbroblasts) is negative for TRPA1 staining (black arrow), and
contains variable numbers of inﬁltrated inﬂammatory cells that
stain positive for TRPA1 (green arrow) (Fig. 1a).
To investigate the expression level of both the proteins at a
cellular level, we employed a panel of LUAD cell lines (HCC-515,
HCC-44, HCC-827, and NCI-H1793) along with the normal lung
cell line (CCL-204) in immunoﬂuorescence (IF) staining
(Supplementary Fig. 2a, b). The results show that the expression
level of these proteins in LUAD is cell-type speciﬁc; both the
proteins are highly expressed in HCC-515 cell line, but only
TRPA1 was detected in HCC-44. Expression level of both the
proteins (especially TRPA1) is low in HCC-827 and NCI-H1793,
and hence both cell lines were not used for further investigation
in this study. Western blot results in Fig. 1c show that TRPA1 is
expressed in LUAD cell lines (HCC-515 and HCC-44), whereas
FGFR2 is only detectable in HCC-515 compared to CCL-204 and
normal bronchial epithelium cell line (LIMM-NBE1; used as an
additional control).
To test for potential co-localization of TRPA1 and FGFR2, we
performed a Duolink proximity ligation assay (PLA) in HCC-515
cells using antibodies that are targeted against endogenous
FGFR2 and TRPA1 (Fig. 1d). In this technique, two proteins
within a sample are labeled with speciﬁc primary antibodies
followed by recognition with secondary antibodies conjugated
with short DNA strands. If the two proteins are co-localized
within less than ~ 40 nm of each other, the two DNA probes are
ligated, a unique new DNA sequence is ampliﬁed, and a color
reaction is developed, resulting in characteristic PLA punctate
staining pattern. Thus, this technique relies on both antibody
recognition and DNA ampliﬁcation, making it more speciﬁc and
sensitive than other microscopy-based techniques20. The presence
of distinct PLA puncta (white arrow pointing at red ﬂuorescent
dots) in HCC-515 cells indicates that the two proteins may indeed
co-localize to form a complex.
Next, we performed an immunoprecipitation (IP) experiment
in HCC-515 cells and HCC-44 cells (Fig. 1e and Supplementary
Fig. 2c–e). In HCC-515 (upper panel), TRPA1-FGFR2 complex
formation was constitutive and prevailed under non-stimulated
conditions, and following stimulation with ﬁbroblast growth
factor 9 (FGF9; FGFR2 agonist) and/or Allyl isothiocyanate
(AITC; TRPA1 agonist). In HCC-44 cells (Supplementary Fig. 2d,
e), IP with anti-TRPA1 pulled down a minimal amount of FGFR2
relative to HCC-515 cells, especially if normalized to the control
lane (IP and IB with anti-TRPA1). Also, an IP with anti-FGFR2
in HCC-44 cells failed to pull down TRPA1.
Similar results were obtained in HEK 293T cells (Supplemen-
tary Fig. 2f, g) that was utilized as our model cell line, since they
are easy to transfect and lack the expression of both the proteins.
Cells were transfected with full-length FGFR2 and TRPA1-GFP
(Supplementary Fig. 2f) followed by IP (Supplementary Fig. 2g).
To further test whether this binding event depends on
FGFR2 stimulation, we co-transfected HEK 293T cells with
TRPA1-GFP and the truncated version of FGFR2 (ΔE, which
lacks the extracellular FGF9-binding region). IP results in Fig. 1f
indicate that TRPA1 can successfully form a complex with both
full-length (FL) FGFR2 and its truncated version. To test whether
FGFR2 intracellular prolines (P810–P813, known to promote
protein–protein interactions in the absence of extracellular
stimulation17–19) are responsible for TRPA1-FGFR2 complex
formation, we fused the last 58 amino acids of the receptor
(residues 764–821) with Glutathione S-transferase (GST) to
generate the wild-type construct (C) or its proline-to-alanine
mutants: P804A (C4), P810A (C10), and P813A (C13).
By performing a GST-pull down using cell lysates of HEK
293T cells transfected with TRPA1 or an in vitro GST-pull down
with puriﬁed TRPA1 (Fig. 1g, h), it became evident that mutating
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00983-w
2 NATURE COMMUNICATIONS | 8:  947 |DOI: 10.1038/s41467-017-00983-w |www.nature.com/naturecommunications
H & Ea
c
h i j
e f g
d
b
N
or
m
a
l
LU
AD
150 kDa
IB: anti-total-FGFR2
IB: anti-total-FGFR2
Duolink
H
CC
-5
15
DAPI Merge
IB: anti-TRPA1
IP: anti-TRPA1
IB: anti-TRPA1
IP: anti-GFP IB: anti-GST
IB: anti-TRPA1
IB: anti-TRPA1
ΔN (53 kDa)
IB: anti-TRPA1
IB: anti-GST
IP: anti-TRPA1
IB: anti-total-FGFR2
IB: anti-total-FGFR2
IP: anti-TRPA1 IB: anti-TRPA1
IB: anti-β-actin
100 kDa
150 kDa
100 kDa
150 kDa
100 kDa 50 kDa
100 kDa
150 kDa
TRPA1
100 kDa
FL ΔE
100 kDa
50 kDa
AITC – –
–+
+ +
+–
C C4 C10 C13
C
1.6
A1-F2
Delta N-F2
1.4
1.2
1.0
0.8
0.6
Fr
a
ct
io
n 
bo
un
d
0.4
0.2
–0.2
0.1 1 10
[FGFR2] (nM)
100 1000 10,000
0.0
C4 C10 C13
FGF9
50 kDa
HCC-515 HEK 293T HEK 293T
Purified TRPA1
FGFR2 TRPA1
100
LIM
M-
NB
E1
CC
L-2
04
HC
C-4
4
HC
C-5
15
FGFR2
TRPA1
90
80
70
60
50
Pe
rc
e
n
ta
ge
40
30
20
10
0
0–2
IHC score
(arbitrary units)
3+
Fig. 1 FGFR2 binds directly to TRPA1 ankyrin repeats via its C-terminal proline-rich motif. a Representative image of haematoxylin and eosin (H&E) stain
and immunohistochemistry (IHC) staining with FGFR2 and TRPA1 antibodies of a lung cancer tissue microarray. Scale bar: 10 μm. Neoplastic epithelial cells
are indicated by the red arrow, inﬂammatory cells by the green arrow, and supporting stroma (ﬁbroblasts) by the black arrow. b Fraction of total LUAD
samples (in percentage) in the tissue microarrays (TMAs) with the indicated pathological scores. c Western blots for the expression levels of FGFR2 and
TRPA1 in LIMM-NBE1, CCL-204, HCC-515, and HCC-44 cell lines. Normalized densitometric values (in relative arbitrary units) are reported in red below
each band and represent the average of three independent experiments. d Duolink assay results with an example of a PLA signal depicted by the white
arrow. Scale bar: 50 μm. eWestern blot analysis of an immunoprecipitation (IP with anti-TRPA1) in HCC-515 cell line followed by immunoblotting (IB) with
the indicated antibodies. f Western blot analysis of an IP in HEK 293T cells transfected with full-length TRPA1 with either full-length FGFR2 (FL) or
extracellular region-truncated FGFR2 (ΔE). IP and IB were performed with the indicated antibodies. g GST pull-down results in HEK 293T cells transfected
with TRPA1 and C, C4, C10, and C13 GST-constructs on GST beads. h GST pull-down experiment with full-length puriﬁed TRPA1 and C, C4, C10, and C13
GST-constructs on GST beads. i Western blot analysis of puriﬁed biotinylated full-length TRPA1 or ankyrin repeats-truncated TRPA1 (ΔN) proteins
immobilized on streptavidin beads and incubated with full-length puriﬁed FGFR2. j Microscale thermophoresis (MST) curve of puriﬁed full-length FGFR2
(F2; titrated in a range of concentrations) with puriﬁed full-length TRPA1 (A1) or ΔN. Apparent dissociation constant Kd for A1-F2 was 122.8± 23.4 nM.
Error bars represent the s.d. of each data point (n= 7)
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prolines 810 and 813, but not 804 (outside the binding region,
and hence used as an additional control) disrupts TRPA1-FGFR2
binding event.
To map the binding site on TRPA1 and investigate the
possibility of its N-terminal ankyrin repeat domain (ARD)
binding to FGFR2 proline-rich motif, we truncated the ARD
(ΔN) to generate a GFP-tagged ΔN construct. Unfortunately, this
construct did not transfect or express well in HEK 293 T cells. To
overcome this technical complication, we puriﬁed, biotinylated,
and immobilized full length TRPA1 and ΔN on streptavidin
beads. We then performed an in vitro pull-down assay with
puriﬁed full length FGFR2, which indicated that truncating
TRPA1 ankyrin repeats abrogates TRPA1-FGFR2 binding event
(Fig. 1i).
We conﬁrmed the binding between the two puriﬁed full-length
proteins in vitro by using microscale thermophoresis (MST in
Fig. 1j). This yielded an equilibrium dissociation constant (Kd) of
122.8± 23.4 nM, which is within the range of Kd values
previously reported for ARD-mediated binding events21, 22. On
the other hand, a binding curve could not be established with ΔN
and full-length FGFR2 (Fig. 1j).
To identify the binding region on ARD, we truncated the last 5
or the last 10 ankyrin repeats of TRPA1-GFP to generate Δ5 and
Δ10 constructs, respectively. Full-length TRPA1, Δ5, or Δ10 were
co-transfected with FGFR2 into HEK 293T cells. Since proline-
motif interactions prevail under non-stimulated conditions18, 19,
we serum-starved the cells prior to performing the IP (Fig. 2a, b;
the efﬁciency of transfection is shown in Supplementary Fig. 2h).
In these cells, pulling-down with TRPA1 and probing for FGFR2
(Fig. 2a with anti-TRPA1 bands as an IP normalization control)
or pulling-down with FGFR2, then probing for TRPA1 (Fig. 2b
with anti-FGFR2 bands as an IP normalization control)
demonstrates that truncating the last 10, but not the last 5
ankyrin repeats abrogates the binding event. These results were
mirrored in the PLA quantiﬁcation of a Duolink assay (Fig. 2c).
To explore this observation further at a cellular level, we
utilized ﬂuorescent lifetime imaging (FLIM) in HEK 293T cells
expressing an empty GFP vector (control; upper panel) or co-
expressing FGFR2-RFP with Δ5-GFP or Δ10-GFP (Fig. 2d, e).
The GFP ﬂuorescence decays were ﬁtted with a single exponential
decay law, whereby a reduced ﬂuorescence lifetime (left shift of
peaks) indicates ﬂuorescence resonance energy transfer (FRET)
due to complex formation. As shown in Fig. 2e, there is a greater
FRET efﬁciency, and thus a higher chance of direct binding of
FGFR2 with Δ5 compared to Δ10 (a shift of 0.09 ns vs. 0.052 ns),
which corroborates the above IP and Duolink results.
The binding event activates FGFR2 and inhibits TRPA1. Next
we wanted to investigate whether the TRPA1-FGFR2 interaction
is of any regulatory signiﬁcance. Knowing that FGFR2 dimer-
ization is essential for its activation, we co-transfected Strep-
tagged FGFR2 and FLAG-tagged FGFR2 into HEK 293T cells
with or without TRPA1-GFP (efﬁciency of transfection is shown
in Fig. 3a) followed by a Duolink assay to test for the co-
localization of Strep-tagged FGFR2 and FLAG-tagged FGFR2
according to the experimental procedure described in the
literature23, 24 (Fig. 3b, c). Our results show that the PLA co-
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inhibitor) treatment. Percentage change in cell viability for each sample with respect to the untransfected control sample (Non) is depicted on the Y-axis. In
the above, error bars, s.d. (n= 3 biological replicates). *P≤ 0.05 and **P≤ 0.01 were determined by two-tailed Student’s t test
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localization signal (number of dots/cells) increases in the presence
of TRPA1, suggesting that TRPA1 promotes dimerization of the
receptor.
To further assess the signiﬁcance of TRPA1-mediated FGFR2
activation, we investigated the phosphorylation level of the
receptor in HEK 293T cells that were differentially transfected
with FGFR2 and/or TRPA1 then left untreated or treated with
FGF9 and/or AITC (Fig. 3d). Interestingly, even without
stimulation, TRPA1 was capable of inducing FGFR2 phosphor-
ylation on the tyrosine residues (653/654) of its activation loop
(Fig. 3d and Supplementary Fig. 3a). To test whether this event is
a consequence of TRPA1-mediated calcium inﬂux rather than the
outcome of TRPA1-FGFR2 binding event, we treated HEK
293T cells (co-expressing TRPA1 and FGFR2) with AITC with or
without TRPA1 antagonist, HC-030031 (Supplementary Fig. 3b).
In both cases, FGFR2 phosphorylation was conserved indicating
that, indeed, it is the binding event that is responsible for receptor
phosphorylation and not TRPA1-activation.
Since phosphorylated FGFR2 is known to be active and capable
of recruiting downstream proteins and subsequently activating
signaling pathways, we performed a high-throughput reverse
phase protein array (RPPA) followed by statistical quantiﬁcation
of the ratio of phosphorylated to total proteins in both HEK 293T
cell line and HCC-515 cell line (Supplementary Fig. 3c–e). Based
on statistical signiﬁcance, it appears that PLC-γ1 pathway
(implicated in cellular invasion25, 26) and the MAPK/ERK
cascade (implicated in cellular proliferation27) are signiﬁcantly
upregulated in cells expressing both TRPA1 and FGFR2 proteins.
To conﬁrm these results, FGFR2-transfected HEK 293T cells
(with/without TRPA1) were serum-starved, left unstimulated or
stimulated with FGF9 and/or AITC, and then probed for
phosphorylated PLC-γ1 (read out for PLC-γ1 pathway activation)
and phosphorylated-p44/42 (ERK1/2, readout for MAPK/ERK
pathway activation). The results indicate that both the pathways
are activated in cells co-expressing both proteins even in the
absence of extracellular stimulation (Fig. 3e; 3rd lane).
It was essential to test whether signaling upregulation is
resulting from TRPA1-mediated calcium inﬂux rather than
TRPA1-mediated FGFR2 activation. Knowing that pathway
activation in HEK 293T cells requires FGFR2 activation (Fig. 3e
and Supplementary Fig. 3c–e), we differentially transfected and
treated HEK 293T cells in the absence or presence of the calcium-
chelating agent, EGTA (Supplementary Fig. 3f). Our results
revealed that AITC-mediated TRPA1 activation could not induce
ERK signaling in the absence of FGFR2. Additionally, chelating
calcium abrogates ERK phosphorylation that is mediated by
FGF9-stimulated FGFR2 (2nd and 6th lanes), but not in the
presence of AITC-stimulated TRPA1 (4th and 8th lane). This
conﬁrmed that: i) AITC alone cannot activate FGFR2 (last lane in
Fig. 3d and Supplementary Fig. 3c–e) and ii) TRPA1 seems to
trigger downstream signaling pathways by binding and activating
FGFR2 independently of the Ca2+ inﬂux through the channel.
Next, we wanted to gain insight into the effect of isolated
TRPA1 on FGFR2. For that, we utilized puriﬁed proteins in an
in vitro dimerization assay, whereby we ran a western blot under
native vs. reducing conditions using beta mercaptoethanol (βME)
in order to disrupt inter-chain disulﬁde bonds that exist in
dimeric FGFR2. On the blot, the potential dimeric band for
FGFR2 (higher molecular weight band detected via anti-FGFR2
antibody) appears to be more prominent in the presence of
puriﬁed TRPA1 (Fig. 3f), which validates the in situ results
obtained in Fig. 3b. Similarly, to assess the effect of TRPA1-
FGFR2 interaction on the in vitro kinase activity of FGFR2,
puriﬁed FGFR2 with its synthetic substrate (Glu-Tyr) were
incubated with ATP in the presence or absence of TRPA1
(Fig. 3g). The results indicate that the kinase activity of the
receptor (auto-phosphorylation and substrate phosphorylation) is
enhanced in the presence of TRPA1. Additionally, we employed a
luminescence kinase assay using puriﬁed proteins (linear
conversion curve used to extrapolate the luminesce-based kinase
activity is shown in Supplementary Fig. 4a). In this case,
luminescence signal (proportional to kinase activity) of full-
length FGFR2 or the intracellular region of FGFR2 (IntraF;
residues 400-821 that encompass FGFR2 kinase domain and the
intracellular TRPA1-binding region) is higher in the presence of
full length TRPA1 and remains unchanged with ΔN (Fig. 3h).
Taken together, the above data indicate that TRPA1 binds to
the C-terminal region of FGFR2 via its ankyrin repeats leading to
receptor phosphorylation and subsequent activation of down-
stream signaling pathways.
We further examined the effect of FGFR2-TRPA1 interaction
on TRPA1 activity. Channel activity was assessed, by measuring
changes in intracellular calcium, in HCC-515 (expressing both
proteins) and HCC-44 cells (lacking FGFR2 expression) treated
with AITC (Fig. 3i, j). The results revealed that HCC-44 cells
incurred a larger increase of intracellular calcium in response to
AITC treatment than HCC-515. Interestingly, the AITC-induced
response of HCC-44 cells was signiﬁcantly reduced when the cells
were transfected with FGFR2 (Fig. 3k, l; efﬁciency of transfection
is shown in Supplementary Fig. 4b). Thus, FGFR2 (and
speciﬁcally its intracellular portion; Supplementary Fig. 4c) has
an inhibitory effect on TRPA1 activity that can be inferred from
the reduced AITC-mediated calcium inﬂux. This was further
validated through patch-clamp experiments performed on HCC-
44 cells (Fig. 3m and Supplementary Fig. 4d).
Since TRPA1-FGFR2 binding event can trigger the activation
of PLC-γ1 and MAPK/ERK pathways, it was essential to
investigate its functional signiﬁcance. For that, we performed a
Boyden chamber invasion assay through a matrigel-coated
porous membrane to mimic the extracellular matrix that the
invasive cells break down to invade through the pores (Fig. 3n).
For the control assay, the chambers with uncoated membrane
were utilized (Supplementary Fig. 4e, f). In this case, differentially
transfected HEK 293T cells were incubated overnight in the
upper chamber in serum starvation media to test their invasive
potential into the lower chamber containing 1% serum as a
chemoattractant (Fig. 3n). We observed that the cells expressing
both TRPA1 and FGFR2 have a higher invasive potential
compared to those cells lacking both or one of the two proteins
(Fig. 3n; upper panel). In the control assay, the chemotactic
potential of the cells was similar (Supplementary Fig. 4e, f).
To determine whether increased invasive phenotype is linked
to TRPA1-FGFR2 binding event, and not just TRPA1 and FGFR2
co-expression, HEK 293T cells were co-transfected with FGFR2
and either with Δ5 TRPA1 or Δ10 TRPA1 (Fig. 3n; bottom
panel). Our ﬁndings demonstrate that truncating the last 10-
ankyrin repeats of TRPA1, not only abrogates the binding event,
but also diminishes the invasive potential of the cells. To test
whether PLC-γ1 pathway is responsible for cellular invasion in
this model system, we inhibited the pathway with PLC inhibitor,
(U73122) or knocked down PLC-γ1 in HEK 293T cells that co-
express FGFR2 and TRPA1 to generate PLC-γ1_KD cell line
(Fig. 3n; Bottom panel). In both cases, the invasive potential of
the cells was signiﬁcantly decreased (Fig. 3o). The efﬁciency of
knockdown and the assay quantiﬁcation results are shown in
Supplementary Fig. 4g; upper panel.
Since cellular proliferation is mainly induced by MAPK
pathway, we tested the effect of TRPA1-FGFR2 on cellular
proliferation using a proliferation/viability MTT assay. For that,
HEK 293T cells were differentially transfected with FGFR2 and
TRPA1 constructs with or without treatment with MAPK
inhibitor, U0126 at 10 µM (efﬁciency of inhibition is shown in
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Supplementary Fig. 4g; bottom panel). Notably, deleting the last
10 ankyrin repeats of TRPA1 or treating HEK 293T with U0126
drastically lowered the proliferative potential of the cells
compared to that of the untreated cells that have been co-
transfected with full-length FGFR2 along with full length TRPA1
or Δ5 TRPA1 (Fig. 3p). This indicates that TRPA1-FGFR2
binding event triggers cellular invasion/proliferation by aber-
rantly activating FGFR2, independent of extracellular stimulation.
TRPA1 expression is reduced upon encounter with astrocytes.
Lung cancer is known to metastasize to the brain1–5, and for that,
we assessed the expression level of both proteins by staining for
them in LUAD brain metastases (Fig. 4a). Consistent with
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published data28–30, the green area on the image that marks the
normal brain tissue showed weak to negative staining for FGFR2
and TRPA1. Unlike with normal brain tissue, FGFR2 is strongly
positive throughout the entire tumor mass, with the ﬁbrovascular
supportive stromal tissue and their hyperplastic ﬁbroblasts being
weakly positive (see arrows). Notably, most of the tumor cells
inﬁltrating the brain lack TRPA1 expression unlike tumor cells in
primary LUAD tissues (Fig. 1a).
To investigate this further, we injected GFP-HCC-515 cells into
the carotid artery of a mouse model system and waited for 3 or
5 days (D3 and D5, respectively) as explained in the Methods
section and in accordance with the previously established
experimental protocol31. 5 days following their injection into
the artery, LUAD cells were observed in the vicinity of the brain
(Supplementary Fig. 4h)
To assess the inﬁltration of GFP-HCC-515 cells into the brain,
ﬂoating tissues of the mouse brain (at D3 and D5 post-injection)
were stained with CD-34 (blood vessel marker) to assess the
extravasation of cancer cells through the blood vessels and into
the brain (Fig. 4b; left panel). By quantifying the percentage of
cells “in” vs. “out” of the blood vessels based on the localization of
GFP-HCC-515 cells and blood vessels (Fig. 4b; right panel), it is
evident that the cancer cells have indeed successfully extravasted
into the brain niche in a time-dependent manner. This provided
us with a model to investigate the mechanism behind TRPA1
depletion in the brain.
Notably, it has been previously shown that in the brain, cancer
cells are encountered by reactive astrocytes that modulate the
expression levels of cancer cells' proteins8. We hypothesized that
such intercellular communication could be responsible for the
downregulation of TRPA1 observed in the cancer cells invading
the brain. To investigate if this is the case, we stained the mouse
brain tissues with the astrocyte marker (GFAP; Fig. 4c), where the
number of reactive astrocytes (GFAP+ cells) concentrated around
GFP-HCC-515 cells was drastically higher at D5 vs. D3 post-
injection (Fig. 4c; bar graph). This was consistent with the
increase in the number of extravasated cancer cells in D5 vs. D3
(Fig. 4b).
To understand the effect of extravasation on TRPA1 expres-
sion, we stained for TRPA1 (cyan colour in Fig. 4d) at D3 and D5.
The zoomed-in image clearly shows the absence of TRPA1
expression in HCC-515 cells at D5 compared to D3 where the
number of TRPA1+ cells in D5 is minimal (bar graph). Thus, we
hypothesized that astrocytes may be responsible for TRPA1
depletion in cancer cells possibly through intercellular commu-
nication as reported with the tumor suppressor protein,
phosphatase and tensin homolog deleted on chromosome 10
(PTEN), in breast cancer8.
To test this hypothesis further at a cellular level, we isolated
astrocytes from the brains of Wistar rats (with GFAP as a marker
for isolation efﬁciency in Fig. 5a; upper panel) and cultured them
to prepare astrocyte-conditioned media (CM) as previously
described8 (see Methods section). Treatment of cancer cells with
astrocyte-derived CM is an efﬁcient method to investigate
intercellular communication between astrocytes and cancer cells
under deﬁned and controlled conditions. This is critical,
especially because the growth factor secretion in the brain niche
is dynamic and dependent on a myriad of mechanistic and
clinical factors8, 32–34.
We observed that by treating HCC-515 cells overnight with
CM media, TRPA1 expression level was signiﬁcantly decreased in
comparison to the levels in those cells treated with serum
starvation (SS) media (Fig. 5a; bottom panel). To test for changes
in cellular characteristics, we probed for the expression of
E-Cadherin (epithelial marker) and N-cadherin (mesenchymal
marker). The results revealed an increase in E-Cadherin level with
concomitant decrease in N-Cadherin level, an indicative feature
of decreased cellular motility35. Notably, the decrease in TRPA1
expression level also resulted in a drastic reduction in the level of
phosphorylation of FGFR2, PLC-γ1, and ERK. These effects were
rescued upon knocking-in of TRPA1 (A1 cell line), but not when
TRPA1 was knocked-in and FGFR2 was knocked-down (A1,
F2-KD cell line in Fig. 5b). These ﬁndings indicate that astrocytes
are inhibiting FGFR2-dependent downstream signaling pathways
in HCC-515 cells by decreasing TRPA1 expression level.
To test for functional signiﬁcance of CM treatment at a cellular
level, we stained for Ki-67, which is known to be a proliferation
marker36 (Fig. 5c, d). Our results demonstrate (based on the
percentage of Ki-67+ cells) that CM treatment reduced HCC-515
proliferative potential, which was rescued upon knocking-in of
TRPA1 in the presence of FGFR2, but not in FGFR2-knockdown
cells (bottom panel). Results obtained from this experiment were
mirrored in an MTT assay (Fig. 5e).
Furthermore, in order for cancer cells to metastasize to the
brain, they need to cross the blood-brain barrier37, 38. Thus, for
physiological relevance and in order to test the effect of CM on
cellular invasion, we performed a transendothelial assay (Fig. 5g,
h) with a chemotaxis assay used as a control (Supplementary
Fig. 4i, j). For that, rat brain endothelial (RBE4) cells were grown
as a monolayer in the upper compartment of a trans-well plate to
reach full conﬂuency. Barrier integrity was validated by the high
expression of tight junction (TJ) proteins with a typical
localization at cellular borders (Fig. 5f). The transendothelial
electrical resistance (TEER) of the brain endothelial monolayers,
indicating the tightness of TJs, reached 150-200 ohm·cm2 on
average, which is within the acceptable range of reported TEER
values in RBE4 models39. By culturing HCC-515 cells on top of
the RBE4-monolayer in SS media (control) or CM media with 1%
FBS-supplemented media in the lower chamber, CM treatment
signiﬁcantly decreased the invasive potential of the cells. On the
other hand, the chemotactic potential of the control cells cultured
in chambers with uncoated membranes was similar
Fig. 4 TRPA1 expression level is signiﬁcantly reduced upon LUAD brain metastasis. a IHC and H&E staining of lung cancer brain metastases. Upper panel:
Normal brain tissue (green area), tumor tissue (black arrows), necrosis (blue arrows), and haemorrhage (red arrows). Middle panel: Higher magniﬁcation
of normal brain (scale bar: 100 μm). Bottom panel: Higher magniﬁcation of metastatic lung cancer (scale bar: 200 μm) shows FGFR2-positive tumor cells
with areas of negatively-stained ﬁbrovascular connective tissue (black arrows). b Left panel: Images of IF staining at 20× magniﬁcation of mouse brain
slices 5 days following injection with GFP-HCC-515. CD-34 (Alexa 555) was used as a blood vessel marker. Scale bars: 20 μm. Right panel: Percentage of
cancer cells located inside vs. outside blood vessels 3 days (D3) and 5 days (D5) following injection. Error bars indicate s.d. *P≤ 0.05. c Left panel: Two
representative images from D5 (one with an additional zoom-in area). GFAP-positive reactive astrocytes (Alexa 647; pseudo colour: magenta) are shown
in the vicinity of extravasating cancer cells (green) as indicated by the white arrows (arrow 1: cancer cell; arrow 2: blood vessel; and arrow 3: astrocyte).
Scale bars: 20 μm. Right panel: Bar graph representation of the number of activated astrocytes present in the vicinity of cancer cells 3 days (D3) and 5 days
(D5) following injection. Cancer cell-associated astrocytes are quantiﬁed within a distance of 150-μm from cancer cells. Error bars indicate s.d. *P≤ 0.05. d
Left panel: TRPA1 expression (Alexa 647; pseudo colour: cyan) in cancer cells 3 days (D3) and 5 days (D5) following injection. Scale bars: 20 μm. Right
panel: Extravasated cancer cells were counted in 20 randomly chosen ﬁelds per brain followed by calculation of TRPA1-positive cells. Error bars indicate s.d.
*P≤ 0.05
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(Supplementary Fig. 4i, j). This effect was reversed upon
knocking-in of TRPA1 in the presence of FGFR2, but not upon
FGFR2 knockdown (Fig. 5g, h). This drop in both invasion and
proliferation may likely be due to the decrease in the
phosphorylation level of PLC-γ1 and ERK detected in Fig. 5b.
Astrocytes abrogate TRPA1 expression via exosomal miR-142-3p.
Finally, we attempted to elucidate the mechanism modulating
TRPA1 expression in LUAD cells upon their encounter with
astrocytes. By recognizing the involvement of astrocyte-secreted
microRNAs (miRNAs) in depleting the expression of proteins in
the brain niche8, 40, 41, we postulated that TRPA1 level may be
signiﬁcantly reduced through an miRNA-mediated mechanism.
These circulating miRNAs are abundant in the brain niche and
are known to be transported as cargo in cell-derived vesicles
called exosomes to mediate cellular communication and
function8, 40–43. Indeed, and via transmission electron micro-
scopy (TEM), we detected the presence of encapsulated particles
in CM that varied in size between 30-100 nm, which were positive
for the exosomal marker, CD63 (Fig. 6a).
In order to explore the effect of exosomes on the level of
TRPA1 mRNA, we treated HCC-515 cells overnight with SS
(control 1), CM, concentrated CM-exosomes, residual
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Fig. 5 Astrocytes decrease the proliferative and invasive potential of cancer cells by reducing TRPA1 expression level. a Upper panel: western blot analysis
of GFAP expression level in astrocytes with HCC-515 cells used as a negative control. Bottom panel: western blot analysis of HCC-515 cells that have been
serum starved (SS) or treated with conditioned media (CM). The blot was probed with the indicated antibodies. Normalized densitometric values are
reported in red above each band throughout the ﬁgure and represent the average of three independent experiments. b Western blot analysis of HCC-515
cells without TRPA1 transfection (−), with TRPA1 transfection and scrambled shRNA (A1) or with TRPA1 transfection and FGFR2 knockdown (A1/F2_KD).
In all cases, blots were probed with the indicated antibodies. c IF of HCC-515 cells stained with the proliferation marker, Ki-67. Scale bar: 50 μm. d Bar
graph quantiﬁcation of (c), where the number of Ki-67+ cells were counted under the same magniﬁcation in 6 random microscopic ﬁelds/sample and
averaged. Error bars indicate s.d. (n= 3 biological replicates). *P≤ 0.05 by two-tailed Student’s t test. e Results of an MTT assay performed overnight and
normalized against the values obtained for SS-treated-cells. Error bars indicate s.d. (n= 3 biological replicates). *P≤ 0.05 by two-tailed Student’s t test. f IF
of tight junction proteins (ZO-1, Occludin and Claudin-5 depicted by white arrows in the zoom-in area) in RBE4 cells with different paracellular permeability
that were grown in a trans-well chamber. TEER measurement of the integrity of the cellular barrier ranged in value between 150 and 200 ohm cm2. Scale
bars: 20 μm. g Representative images of a transendothelial assay with RBE4 monolayer from (f) utilized as a cellular barrier on top of which HCC-515 cells
were incubated in SS media or CM media with 1% serum-supplemented media in the lower chamber. Images were taken at 20× magniﬁcation. Scale bar:
100 μm. h Quantiﬁcation of the transendothelial assay results, where the number of invaded cells were counted in 8 different microscopic ﬁelds. Error bars
indicate s.d. (n= 3 biological replicates). *P≤ 0.05 by two-tailed Student’s t test
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supernatant from the exosomal extraction process (control 2),
and CM collected from dimethyl amiloride (DMA; inhibitor of
exosomal release8, 42, 43) treated astrocytes (Fig. 6b). Evidently, in
the presence of exosomes, TRPA1 in cancer cells was depleted
indicating that astrocytes are indeed acting on HCC-515 cells via
an exosome-mediated mechanism. Notably, in all these growth
conditions, and whenever relevant, exosome-free FBS was utilized
instead of regular FBS to ensure the speciﬁcity of the experiment.
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median of overall survival (OS) in months is shown. e, f Bar graphs showing the level of miRNA in exosomes and differentially treated HCC-515 cells. g Bar
graph representation of the changes in TRPA1 mRNA levels in HCC-515 cells following their treatment with SS media only, SS media + anti-miR (miR-142-
3p inhibitor) and SS media + miR-142-3p mimic. h Bar graph of the 3′-UTR luciferase assay results obtained from HEK 293T cells in the abence or presence
of mimics. i IF staining images of the intercellular transfer of miR-142-3p, 4 h or 24 h following the co-culture of HCC-515 (expressing an empty GFP
vector) with astrocytes that have been loaded with Cy-3-labeled miR142-3p. GFAP (Alexa 647 with magenta as a pseudo-colour) was utilized as an
astrocytic marker to distinguish them from cancer cells. Scale bar is 50 μm. j Bar graph representation of the results from i) counted at 20× magniﬁcation in
eight randomly selected microscopic ﬁelds. kWestern blot analysis of HCC-515 after variable overnight treatments followed by probing with the indicated
antibodies. Normalized densitometric values represent the average of three independent experiments. l Western blot analysis of HCC-515 cells 6 h post-
transfection with the indicated constructs following their overnight treatment with exosomes. The blot was probed with the indicated antibodies. In the
above, error bars, s.d. (n= 3 biological replicates). *P≤ 0.05 and **P≤ 0.01 by two-tailed Student’s t test
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To establish a better link between astrocyte-derived exosomes
and TRPA1 expression level in HCC-515 cells, we investigated all
potential TRPA1-targeting miRNAs in LUAD by utilizing The
Cancer Genome Atlas (TCGA) database. The main selection
criterion used was to identify miRNAs that negatively correlate
with TRPA1 expression, but positively correlate with patient
overall survival (OS) in LUAD patients. Two miRNAs were
identiﬁed: miR-148-3p and miR-142-3p (Fig. 6c, d and
Supplementary Fig. 5). Notably, and in separate studies, it has
been shown that these (species-conserved) miRNAs, can suppress
non-small cell lung cancer progression44, 45. They have also been
shown to exist in the brain microenvironment46, yet the link
between these miRNAs and LUAD in the brain metastatic niche
was never reported.
To determine which of the two miRNAs is implicated in our
mechanism, we measured their level in exosomes and uncovered
that miR-142-3p, but not miR-148-3p, is abundant (Fig. 6e). On
the other hand, in HCC-515 cells, miR-148-3p is more abundant
than miR-142-3p with a surge in the level of the latter upon
treatment of the cells with puriﬁed exosomes (Fig. 6f). Thus, there
is a possibility that miR-142-3p is being transferred from
astrocytes to HCC-515 cells in astrocyte-derived exosomes
leading to TRPA1 depletion.
To investigate the direct effect of miR-142-3p on TRPA1,
HCC-515 cells were differentially treated with miR-142 mimic or
inhibitor in SS media. As the results indicate, miR-142-3p can
indeed regulate the mRNA level of TRPA1 (Fig. 6g). Additionally,
we examined the binding of miR-142-3p to the 3′-untranslated
region (UTR) of TRPA1, given the requirement for a microRNA
to bind to the 3’-UTR of target mRNA in order to deplete protein
expression47. Data was collected by measuring the luciferase
activity of TRPA1 3′-UTR reporter clone in HEK-293T cells. The
results show that the signal is signiﬁcantly reduced in the
presence of miR-142-3p mimic, but not miR-148-3p mimic,
conﬁrming that miR-142-3p is directly acting on TRPA1
(Fig. 6h).
To investigate the physical transfer of miR-142-3p from
astrocytes to HCC-515 cells, Cy-3 labeled miR-142-3p particles
(red) were transfected into astrocytes (magenta) that were
subsequently co-cultured with GFP-HCC-515 cells (Fig. 6i, j).
Our ﬁndings show that Cy-3+ cancer cells are detected post
incubation with astrocytes, signifying the transfer of miR-142-3p
from astrocytes to HCC-515 cells.
Finally, to elucidate the link between this intricate mechanism
and TRPA1-FGFR2 interaction, we treated HCC-515 cells with SS
media, exosomes, CM (DMA), and miR-142-3p inhibitor
(Fig. 6k). As shown, treatment with exosomes abrogated TRPA1
expression, which was rescued with CM (DMA) and miR-142-3p
inhibitor treatment. These results were mirrored in the level of
phosphorylation of FGFR2. To test if such an effect is due to
ankyrin-proline binding event, exosome-treated HCC-515 cells
were transfected with full-length TRPA1, Δ10, or Δ5 (Fig. 6l).
Transfection with full length TRPA1 or Δ5 (both of which lack
the 3′-UTR) rescued FGFR2 phosphorylation yet Δ10 (which is
incapable of FGFR2 binding and also lacks the 3′-UTR) failed to
do so. This indicates that astrocytes are modulating cellular
proliferation and invasion by decreasing TRPA1 expression level
and subsequent FGFR2 activity.
Discussion
TRPA1 mediated protein–protein interactions, their consequent
regulatory effects, and roles in LUAD remain largely unknown.
Interestingly, the role of TRPA1 as an invasive and prognostic
marker in cancer12, 48 has recently been reported, reﬂecting the
growing interest in deciphering its oncogenic function. By
building on the previously established role of FGFR2 in LUAD17–
19 and the possibility of ankyrin repeats binding to proline-rich
motifs15, we investigated the presence of a potential TRPA1-
FGFR2 binding event in LUAD and its contribution to the
oncogenic process.
Our study clearly indicates that FGFR2 and TRPA1 form a
complex, in which the ankyrin repeats of TRPA1 bind to the C-
terminal proline-rich region of FGFR2. This interaction inhibits
the channel (possibly through structural changes in TRPA-1
conformation), yet acts as a possible conformational scaffold that
induces receptor activation independent of extracellular stimu-
lation leading to aberrant proliferation and invasion. This
hypothesis, however, opens doors to further future investigations
to decipher the structural complexity entailing such an intricate
binding event.
Thus, our ﬁndings not only identify the regulatory function of
TRPA1 ankyrin repeats, but also highlight the importance of
ankyrin–proline interactions in tumor progression. This intro-
duces LUAD as a potential TRPA1-modulated channelopathy,
with TRPA1 and FGFR2 acting as valuable cancer biomarkers.
In addition, our study brings to light the mechanism by which
astrocytes target inﬁltrating LUAD cells via TRPA1-depleting
exosomal miRNA, thereby interrupting the FGFR2-driven
oncogenic process at early time points. The trigger for exoso-
mal release by astrocytes, however, remains to be unveiled. Based
on previous reports on the crosstalk between cancer cells and
astrocytes in the brain, which modulates protein expression in
tumour cells8, we postulate that the release of chemokines by
cancer cells can attract astrocytes and induce the release of exo-
somal miRNA.
Notably, due to the dynamic nature of the brain micro-
environment, the effect of miRNA on TRPA1 might be overcome
by cancer cells at later stages49. Nonetheless, the herein described
miRNA-driven machinery might explain the clinical latency
between the appearance of early circulating lung cancer cells and
development of brain metastases.
Methods
Cell culture. Human Embryonic Kidney cells (HEK 293T) and normal lung
ﬁbroblast cell line (CCL-204; CCD-16Lu) were purchased from ATCC®. Normal
bronchial epithelial cell line (LIMM-NBE1) was provided by Dr. Philip Egan.
Human lung adenocarcinoma cell lines (HCC-44; CSC-C0542) were purchased
from Creative Bioarray. Human lung adenocarcinoma cell lines (HCC-515,
HCC-827 and NCI-H1793) were provided by Dr. Ignacio I. Wistuba. All cell lines
have been tested for mycoplasma contamination and were cultured in Dulbecco’s
modiﬁed Eagle’s high-glucose medium (DMEM), supplemented with 1% Gibco®
Antibiotic-Antimycotic (Life Technologies™) and 10% v/v Gibco® fetal bovine
serum (Life Technologies™). All cells were incubated at 37 °C and 5% CO2. The
immortalized cell line RBE4 (rat brain endothelial cells) was provided by Professor
N. Joan Abbott) and used for transendothelial invasion assays50. Primary cultures
of GFAP+ rat astrocytes were obtained from 5-7 days old Wistar rats. According to
the protocol51, 52, cerebral cortices were placed in fresh PBS free of Ca2+ or Mg2+
(Sigma Aldrich) and minced in the same buffer containing 0.25 mg/mL trypsin for
15 min at 37 °C following meninges removal. Trypsin was deactivated by 16 μg/mL
soybean trypsin inhibitor (type I-S; Sigma Aldrich), 0.5 µg/mL DNase I (EC
3.1.21.1 type II from bovine pancreas, 125 kU/mL, Sigma Aldrich) and 0.3 mM
MgSO4. The mixture was centrifuged at 400 g for 5 min and the cell pellet was
resuspended in 6.8 mL of buffer solution containing 100 µg/mL soy bean trypsin
inhibitor, 0.5 µg/mL DNase I and 1.5 mM MgSO4. A 10 mL stripette was used to
triturate the resuspended cells and the cell suspension was added into 120 mL of
Eagle’s minimal essential medium supplemented with 10% fetal calf serum (v/v)
and 1% (v/v) penicillin-streptomycin (Invitrogen), then aliquoted into 75 cm2
ﬂasks and cultured in 37 °C, 5% CO2. Six hours later, the cells were washed and
cultured in DMEM at 37 °C, 5% CO2 so that the background composition of CM is
similar to SS with the only variable being the exosomes that astrocyte have secreted
into CM. CM collected from serum-starved astrocytes was prepared by following
the established protocol8, 53, 54.
Reagents. FGF9 (catalogue # 273-F9-025) was purchased from R&D Systems.
METAFECTENE® PRO (#T040) was purchased from Biontex. TRPA1 antibodies
were purchased from Alomone (#ACC-037) and Santa-Cruz (#sc-166469). Total
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FGFR2 antibody (#sc-122) was purchased from Santa-Cruz. pFGFR2 (#3471),
pERK (#4370), Total ERK (#9102) β-actin (#4970), Flag (#8146), Ki-67 (#9449), β-
tubulin (#2146), Zona Occludin-1 (#5406), Claudin-5 (#4933), IgG antibody
(#2729), anti-GFP (#2956) antibodies along with U0126 (#9903) were purchased
from Cell Signalling. U73122 (#1268) was purchased from TOCRIS. NEB 5-alpha
competent E.Coli (high efﬁciency) (#C2987H) cells purchased from New England
Biolabs, were used for transformation. TRPA1 inhibitor HC030031 (#2896) was
purchased from Tocris bioscience. ATP (#9804) and kinase buffer (#9802) were
purchased from Cell Signalling. Occludin (H-279) (sc-5562) antibody, validated
shRNAs18, 55 (sc-29218-V, sc-108080, and sc-29452-V), and DMA (sc-202459)
were purchased from Santa Cruz Biotechnology, Inc. Strep antibody
(# ab76949) was bought from abcam. CD-63 antibody (#GTX41877) from Gene-
Tex was utilized as an exosomal marker (exosomal proteins were extracted using
the Total Exosome RNA and Protein Isolation kit (#4478545, Invitrogen). All
antibodies were used in 1:1000 dilutions for western blots.
Western blotting and pull downs. The cells were left untransfected, or transfected
using METAFECTENE® PRO (#T040) from Biontex as previously described18, 19.
Cells were serum-starved overnight and left un-stimulated or treated with 20 ng/ml
FGF9 for 30 min and/or 10 mM AITC for 5 min and/or inhibitors. For extracellular
calcium-free condition, the cells were pretreated with calcium-chelating solution
(containing 165 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 10 mM Hepes, 10 mM
Glucose, and 1 mM EGTA) for 2 h prior to stimulation. After cells lysates were
obtained using HEPES lysis buffer, 50 μg of proteins were used for SDS-PAGE and
transferred onto PVDF membranes by wet transfer. The membranes were blocked
with 5% milk or 3% bovine serum albumin (BSA) and incubated with primary
antibodies overnight at 4 °C. After washing, the membranes were incubated with
secondary antibody for 40 min at room temperature and washed again prior to
visualization with chemiluminescence reagents (Thermo Scientiﬁc Pierce® ECL
Western Blotting substrate, #32106). For GST-pull down, GST constructs were
immobilized on glutathione-sepharose beads, incubated with cell lysates or puriﬁed
protein followed by western blotting analysis as previously described18. For biotin-
streptavidin pull down, hTRPA1 and Δ1-688 hTRPA1 proteins were biotinylated
with EDC-based carboxyl-biotinylation reagent (EZ-Link™) from ThermoFisher
Scientifc. This was followed by pull-down of puriﬁed FGFR2 using 0.3 μg/μL of
biotinylated bait puriﬁed proteins (immobilized on Streptavidin beads) with
Pierce™ Biotinylated Protein Interaction Pull-Down Kit (# 21115) followed by
western blot analysis. For immunoprecipitation, cell lysates were incubated with
Protein A/G Plus Agarose beads (Santa-Cruz, sc-2003) and the experiment was
carried out according to the manufacturer’s instructions followed by western blot
analysis.
Calcium imaging. Cells were serum starved prior to incubation with 1 μM Fura-2-
AM and 0.01% pluronic acid in EC solution (160 mM NaCl, 2.5 mM KCl, 1 mM
MgCl2, 2 mM CaCl2, 10 mM Hepes, and 10 mM Glucose) at 37 °C for 45 to 60 min.
The cells were excited at 340 nm and 380 nm alternatively every 2 s and the calcium
response was indicated by the change in ﬂuorescence intensity of Fura-2 at
340/380 nm (F340/F380). Treatment with ionomycin (#I24222, ThermoFisher
Scientiﬁc) at the end of each experiment was used as a positive control. Every
experiment, n, is comprised of the average response of 20–40 cells. Each experi-
ment was performed in triplicates. The imaging was conducted with an inverted
Nikon Eclipse TE-2000 microscope, 10X objective, Polychrome V monochromator,
IMAGO CCD camera, and TILLvision 4.5 software. In calcium experiments
throughout the paper, AITC was used at a concentration of 100 μM.
Electrophysiology. Fragments of coverslip with attached wild type HCC-44 cells
or FGFR2 overexpressing HCC-44 cells were transferred to a continuously perfused
(3-5 ml/min) recording chamber mounted on an Olympus (Tokyo, Japan) CK40
inverted microscope. Whole-cell patch clamp recordings were obtained from cells
voltage-clamped at -60 mv using an Axopatch 200B ampliﬁer/Digidata 1322 A
interface controlled by Clampex 10 software (Molecular Devices, Foster City, CA).
The standard perfusate (pH 7.35, 22± 1 °C) was composed of 140 mM NaCl, 5 mM
KCl, 10 mM HEPES, 1 mM MgCl2, and 1.5/2 mM EGTA/CaCl2. Patch pipette
resistance was 4-6MΩ, series resistance (SR) was compensated (60–80%) after
breaking into the cell and periodically monitored throughout the experiment. If SR
increased ( > 20%) the experiment was terminated. The intracellular solution (pH
7.35) consisted of 145 mM KCl, 10 mM HEPES, 2 mM MgCl2, 10 mM EGTA, 2
mM K2ATP, and 0.5 mM GTP. Data were digitized at 5KHz and low-pass ﬁltered
at 2.5 KHz. In this experiment, n 3 biological replicates with multiple cells in each.
MST. The NanoTemper NT.115 machine was used for the thermophoresis
experiment as previously described18. Puriﬁed human TRPA1 with and without the
N-terminal ankyrin repeat domain (Δ1-688 hTRPA1) was labeled with Alexaﬂuor
488, and passed through a NAP-5 column (GE Healthcare) to eliminate any
unincorporated excess dye. After calculating the concentration of labeled protein, it
was used in a constant concentration of 83 nM for the thermophoresis experiment.
Titration series were made with 1:1 dilution of puriﬁed FGFR2. The experiment
was performed in triplicates (repeated 3-8 times) at LED 10–50% and MST power
of 40–80%. PBS was supplemented with 0.014% F-14 to solubilize membrane
proteins in solutions as previously described56, 57. Results of the repetition mea-
surements in the same capillary type with the same IR Laser-power were exported
to a txt-ﬁle and analyzed with GraphPad Prism software. The baseline was sub-
tracted from each individual experiment and the individual repetition was divided
by the amplitude (difference between the unbound and bound state) obtained by
ﬁtting the experiment using the Monolith Software. The Y-Axis on the graph
represents the “Fraction bound”. Error bars represent the standard deviation of the
mean.
Protein expression and puriﬁcation. Mammalian expression full-length receptor
constructs (FGFR2; HG10824-CF and HG10824-ACR) were purchased from Sino
Biological Inc. Strep-tag mammalian plasmid (OGS1159-5UG) was purchased
from Sigma. PGEX vector was purchased from GE Healthcare. Full-length GFP-
tagged TRPA1 lacking the 3’-UTR (RG219290; coding sequence) was purchased
from OriGene. These constructs were used in cloning. Expression and immobili-
zation of GST constructs on glutathione beads was carried out as previously
described18. Brieﬂy, the relevant constructs were transformed into competent cells
that were used to inoculate antibiotic-containing LB media. The culture was grown
to an OD600 at 37 °C with constant shaking, then the cells were collected by
centrifugation and lysed. Proteins from the cleared extract (ﬁltered supernatant)
were eluted, concentrated, and analyzed via SDS-PAGE to assess their purity.
Customized puriﬁed full-length FGFR2 was purchased from OriGene and
utilized according to manufacturer’s instructions. Puriﬁed FGFR2 with His-tag
(truncated version IntraF; residues 400-821) was purchased from Sino Biological
Inc. The N-terminally His-tagged constructs of human TRPA1 with and without
the N-terminal ankyrin repeat domain (Δ1-688 human TRPA1) were
overexpressed in the Pichia pastoris expression system and puriﬁed as previously
described58. After Ni-NTA puriﬁcation, the proteins were desalted and the buffer
was changed to PBS supplemented with 0.014% F-14 in a PD-10 column (GE-
Healthcare). The proteins were concentrated with Vivaspin 6 with a 100 kDa
molecular weight cut-off (Sartorius Stedim Biotech). The protein concentration was
determined by measuring the absorbance at 280 nm using a NanoDrop
spectrophotometer. Any β-mercaptoethanol used in the puriﬁcation step was
removed before the studies on human TRPA1 and Δ1-688 human TRPA1 were
undertaken.
Kinase assays. Reactions of 20 ng, puriﬁed FGFR2 (full-length or cytoplasmic
domain (ΔE)) with/without human TRPA1 and/or Δ1-688 human TRPA1 (ΔN),
with/without poly(Glu-Tyr) peptide (4:1 or 1:1 molar ratio) were incubated in
kinase buffer (#9802 were from Cell Signalling) containing 5 mM ATP,MgCl2 and
Na3VO4. Reaction mixtures were incubated at 30 or 37 °C for 20-30 min. Reactions
were quenched by adding EDTA (prepared in 10 mM HEPES, pH 7.5) to a ﬁnal
concentration of 25 mM. Samples were then utilized for western blot analysis. The
ADP-Glo™ kinase assay (Promega, #V6930) was also used as an additional method
to detect FGFR2 kinase activity in 96-well format according to manufacturer’s
instructions and as previously described59.
Invasion assay and transendothelial invasion assay. Invasion assays were per-
formed as previously described18. In brief, 5 × 104 cells were seeded into the upper
chamber of Matrigel Invasion Chambers and Control inserts (Corming, #354480
and #3354578, respectively) with 8 μm porous membrane in serum starvation
media. The lower chamber contained 1% FBS media. After 24 h incubation at
37 °C, the upper chambers were cleaned so that there were no cells attached in the
inner part, without disturbing the outer side of the porous membrane in which the
cells had invaded. After air-drying, the invasive cells were stained (Thermo Sci-
entiﬁc quick-diff™ kit, #102164) and counted using the Invitrogen™ EVOS™ FL Cell
Imaging System - Thermo Fisher Scientiﬁc. The transendothelial assay was adapted
from the previously reported methods60, 61 The RBE4 monolayer was formed, by
seeding 5 × 105 RBE4 in the upper chamber of a Matrigel Invasion Chambers
(Corming, #354480), and conﬁrmed by IF-detection of tight junction markers and
transendothelial electrical resistance (TEER) measurements using the STX3 elec-
trode and EVOM2 epithelial voltohmmeter (World Precision Instruments, Sar-
asota, FL, USA). TEER values were measured starting from 24 h after seeding the
transwell model with cells, whereby the values obtained with EVOM2 were sub-
tracted from the ohms reading of the blank control (no cells on coated ﬁlter)
multiplied by membrane surface to get the TEER in ohms.cm2. Readings were
carried out in triplicates (n= 3).
MTT. Serum-starved cells or cells grown in conditioned media were left untreated
or treated with 10 µM U0126 for 2 h prior to the MTT assay performed in 12-well
plates (3 biological replicates with 3 technical replicates for each). For the assay, 5
mg/ml of MTT (#M5655) was dissolved in RPMI-1640 without phenol red (#.
R7509) and the solution was ﬁltered using 0.2 μm ﬁlter. Both reagents were pur-
chased from Sigma Aldrich. Brieﬂy, MTT stock solution (5 mg/ml) was added to
equal one-tenth the volume of the original culture media and incubated for 3 h and
the converted dye was solubilized with 0.1 N HCl in absolute isopropanol followed
by measuring the absorbance at a wavelength of 570 nm with background sub-
traction at 630–690 nm. All assays included blank wells containing medium only,
untreated control cells, and test cells of interest. In general, the average values from
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triplicate readings were determined after subtracting the average value from the
blank. The normalization control (such as serum starved cells) represents 100% cell
viability. The A570 values of other conditions were divided by the negative control
value to determine the percentage change in cell viability for each condition.
Duolink assay. The Proximity-Ligation Assay (PLA) from Sigma-Aldrich was used
in an experiment involving 3 biological replicates each with 3 technical replicates;
whereby cells expressing FGFR2 and/or TRPA1 were ﬁxed with 4% paraf-
ormaldehyde and then permeabilized with 0.5% NP-40 in PBS. Cells were incu-
bated in blocking buffer (8% FBS, 0.5% NP-40 in TBS) at room temperature for 30
min, and then in primary antibody (1:100, anti-TRPA1 and anti-FGFR2) at 4 °C
overnight. Next, the cells were incubated with the PLA probes solution for 1 hour at
37 °C, then with Ligation solution for 30 min at 37 °C and last with the
ampliﬁcation-Polymerase solution for 100 min at 37 °C. The cells were left to air-
dry in the dark and image acquisition was carried out following mounting of cells
on glass slides, using mounting medium containing DAPI. Number of spots/cell
was quantiﬁed in multiple (5-8) microscopic ﬁelds, averaged, and then used to
generate bar graphs.
Immunoﬂuorescence. Cells cultured on glass coverslips were ﬁrst washed in PBS,
and then ﬁxed in 4% paraformaldehyde for 20 min at room temperature. After
washing with PBS, the cells were permeabilized in 0.5% NP-40 in PBS for 5 min
and then washed again with PBS. The cells were blocked in blocking buffer
containing 8% FBS and 0.5% NP-40 in TBST for 30 min at room temperature.
The cells were washed with PBS and then incubated in primary antibody (1:100) at
4 °C overnight. After washing with PBS, the cells were incubated in secondary
antibody (1:500) and phalloidin (1:250) for 2 h and then washed with PBS. The
cells were mounted on glass slides using mounting media containing DAPI, sealed
with nail polish, and then imaged using a confocal microscope or EVOS FL
microscope.
Immunohistochemistry. IHC staining of the TMA (# LUC1021 Pantomics) and
brain metastases tissues provided by Leeds Multidisciplinary Research Tissue Bank
was performed as previously described17 using Access Retrieval Buffer Menarini
Diagnostics (Berkshire UK). FGFR2 (1:250) TRPA1 (1:75) were diluted in an
Invitrogen antibody diluent, Life Technologies (Paisley UK). Detection was per-
formed with the Menarini X-Cell Plus detection system. Lung cancer patient tissues
were provided by the Multidisciplinary Research Tissue Bank that collects and
stores the anonymized data and samples from patients who have given full per-
mission for their samples to be used in research.
FLIM. HEK-293T cells co-transfected with RFP-FGFR2 and Δ5-GFP or Δ10-GFP
were cultured on glass coverslips. Serum-starved cells were ﬁxed with 4% w/v
paraformaldehyde for 20 min and mounted with mounting buffer. Confocal data
were collected with an inverted confocal microscope system (Leica TCS SP2) and
two internal photomultiplier tube (PMT) detectors (one displaying the GFP
emission and the other one the RFP emission). FLIM data were collected with the
same microscope system and a GaAsP hybrid detector (Becker & Hickl HPM-100).
The samples were excited with a picosecond diode laser (Hamamatsu PLP-10 470)
at 467 nm. The repetition rate of the laser was always 50 MHz, with pulse duration
~90 ps. A 63 × 1.2 NA water-immersion objective was used to acquire the images.
A line scan speed of 400 Hz and an image size of 512 × 512 pixels were used for
acquiring the confocal images. The FLIM images were acquired with an image size
of 256 × 256 pixels. Images decays were analyzed, averaged, and ﬁtted with a single
exponential-decay model with SPCImage (Becker & Hickl). The GFP ﬂuorescence
lifetime histograms were created in Matlab.
MicroRNA labeling and luciferase assay. Synthetic miRNA mimics, anti-miR,
and negative control miRNAs were purchased from ThermoFisher Scientiﬁc, and
then labeled when needed and transfected as recommended8, 62. Brieﬂy, synthetic
miRNA were left unlabeled or labeled with Cy3 using the Silencer® siRNA labeling
kit (#AM1632) from Life Technologies. For labeling, miRNA142-3p was incubated
for 1 hour at 37 °C in the dark, and then precipitated with ethanol. 100 pmoles of
unlabeled/labeled miRNA or anti-miR were transfected into cells grown in 10-cm
dishes and cells were incubated for 24 h (in the case of HEK 293T cells) or 48 h in
the case of astrocytes that were later co-cultured with LUAD cells at 5:1 ratio and
utilized for imaging. For TRPA1 3’-UTR luciferase reporter assay, cells with
miRNA mimics (ThermoFisher Scientiﬁc) and MISSION(R) 3’UTR Lenti GoClone
(TM) TRPA1 (HUTR10124) from Sigma Aldrich were used to measure luciferase
reporter activity with Mission Lightswitch Luciferase Assay (#MLS0001) from
Sigma Aldrich according to manufacturer’s protocol, with 3 biological replicates
each with 3 technical replicates.
Quantitative PCR qPCRanalysis of mRNA and miRNA levels. Total RNA and
miRNA extraction from cells was performed using the mirVana™ miRNA Isolation
kit (#AM1560, #AM1561) from Life Technologies. For TRPA1 mRNA measure-
ments, ﬁrst strand cDNA was synthesized in 20 μl reactions using Superscript II RT
(Invitrogen) with 1 μg total RNA and random primers (250 ng). Brieﬂy, the cDNA
strand was diluted 1 in 5 with molecular biology grade water prior to use in qPCR
reactions. TRPA1 mRNA expression was assessed using a TaqMan® gene expres-
sion assay (Assay ID Hs00175798_m1; Applied Biosystems). qPCR was performed
in 20 μl reactions containing 10 μl TaqMan® gene expression master mix (Applied
Biosystems), 1 μl TaqMan® gene expression assay, 2 μl of diluted cDNA template,
and 7 μl molecular biology grade water. Levels of TRPA1 expression were nor-
malized to expression of an endogenous control gene, succinate dehydrogenase
complex subunit A (SDHA; Assay ID Hs00417200_m1). For miRNA levels, cDNA
template for use in qPCR was synthesized using the TaqMan® Advanced miRNA
cDNA Synthesis Kit (Applied Biosystems) with 10ng total RNA. Brieﬂy, cDNA was
diluted 1 in 10 with molecular biology grade water prior to use in qPCR. Taqman®
Advanced miRNA assays were used to assess the levels of hsa-miR-142-3p (Assay
ID 477910_mir) and hsa-miR-148a-3p (Assay ID 477814_mir). qPCR was per-
formed in 20 μl reactions containing 10 μl 2X Fast Advanced Master Mix
(Advanced Biosystems), 1 μl TaqMan® Advanced miRNA Assay, 5 μl of diluted
cDNA template and 4 μl molecular biology grade water. Control miRNA used for
normalization was hsa-miR-26a-5p (Assay ID 477995_mir). All reactions were run
on a real-time PCR system (Applied Biosystems) and analysed using the com-
parative Ct (ΔΔCt) method (2−ΔΔCt with logarithm transformation).
Transmission Electron Microscopy (TEM). Negative stained grids were prepared
using carbon-coated copper grids that had been glow-discharged for 30 s. The
sample was blotted and subsequently stained with two drops of 1% Uranyl acetate
before drying and imaging. The grids were imaged using a FEI T12 microscope
ﬁtted with a 2 K × 2 K. Gatan CCD camera operating at 120 kV was used to
examine the samples.
Staining of ﬂoating sections and IF. All procedures were approved by the Uni-
versity of Leeds Animal Welfare & Ethical Review Committee (AWERC), and
performed under the approved UK Home Ofﬁce project license in line with the
Animal (Scientiﬁc Procedures) Act 1986 and in accordance with the UK National
Cancer Research Institute Guidelines for the welfare of animals. The CB17/scid
mice used for the study were 6–8 weeks old females bred in-house at St. James’s
Biological Services, University of Leeds. Cancer cells (1 × 105) were injected into the
left internal carotid artery in a total volume of 50 µL as previously described31.
Three and 5 days after administration of cancer cells into the carotid artery, the
mice were terminally perfused with PBS containing heparin and then with 4% PFA.
After the brains were isolated, they were ﬁxed in 4% PFA overnight at 4 °C and
then transferred to a 25% sucrose solution (200 mL: 50 g sucrose, 0.5 M NaH2PO4,
and 0.5% Na2HPO4) and incubated at 4 °C until they had sunk (3 days). 35-40 μm
sections were sliced from the brains using a cryotome and placed into PBS for
immediate staining, or were stored at −20 °C using Walter’s Antifreeze (100 mL:
0.157 g NaH2PO4, 0.82 Na2HPO4 × 2H2O, 30 mL Ethyleneglycol, 30 mL glycerol).
For staining, ﬂoating sections were placed in 12-well plates and washed 3 times
with PBS for 10 min. All incubations were performed on the shaker. Sections were
incubated with blocking buffer (10% goat serum, 0.3% Triton-X-100 in PBS) for
30–60 min and then incubated with the primary antibody diluted in 0.1–0.2 mL
blocking buffer. After washing 3 times with PBS for 10 min, the sections were
incubated with secondary antibody in blocking buffer for 2 h at room temperature
and then washed again with PBS 3 times. The sections were incubated with DAPI
(1:5000 of 10 mg/mL of stock) for 10 min and then washed again with PBS. The
sections were treated with ProLong Gold Antifade (Life Technologies, P36930),
mounted on glass slides, and left to dry. Images were obtained using an EVOS FL
microscope.
Quantiﬁcation of extravasation and TRPA1 expression levels. To detect the
GFP-tagged tumor cells, ﬂoating brain tissues were stained with different combi-
nations of anti-GFP, anti-CD34, anti-TRPA1, and DAPI to visualize localization of
cancer cells and blood vessels. The position of extravasated cells inside or outside
blood vessels was determined for each detected cell; for this purpose every fourth
section throughout the entire mouse brain was analyzed. At both time point (days 3
and 5), four brains were examined (n= 4). Sixty randomly chosen events in each
mouse were examined per time point. The percentage of intravascular vs. extra-
vascular tumor cells was calculated.
Quantiﬁcation of astrocyte association with LUAD cells. Following injection
of LUAD cells into the carotid artery, the brain tissues were stained for GFAP
to detect astrocytes and co-stained for CD-34 and/or GFP to detect the cancer
cells. The number of reactive astrocytes located within a distance of 150 μm
from the cancer cells were considered to be cancer-cell-associated astrocytes.
The number of reactive astrocytes was counted for 25 randomly chosen events
per brain.
RPPA. RPPA was performed by the Reverse Phase Protein Array Facility within
Edinburgh Cancer Research Centre at the Institute of Genetics and Molecular
Medicine (IGMM), Western General Hospital Campus, University of Edinburgh.
The abundance of total protein and phosphorylated protein epitopes was quantiﬁed
using the Zeptosens RPPA platform as previously described63. In brief, following
differential transfections and treatments, the cell culture medium was removed and
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the cells were lysed with CLB1 buffer (Zeptosens, Bayer) for 30 min. Cell lysates
were normalized to a uniform protein concentration with spotting buffer CSBL1
(Zeptosens-Bayer) prior to preparing a ﬁnal 4-fold concentration series of: 0.2;
0.15; 0.1, and 0.75 mg/ml. The diluted concentration series of each sample were
printed onto Zeptosens protein microarray chips (ZeptoChipTM, Zeptosens-Bayer)
under environmentally controlled conditions (constant 50% humidity and 14 °C
temperature) using a noncontact printer (Nanoplotter 2.1e, GeSiM). A single 400
Pico litre droplet of each lysate concentration was deposited onto the Zeptosens
chip. A reference grid of AlexaFluor647 conjugate BSA consisting of 4 column × 22
rows was spotted onto each sub-array, each sample concentration series were
spotted in between reference columns. After array printing, the arrays were blocked
with an aerosol of BSA solution using a custom designed nebulizer device
(ZeptoFOGTM, Zeptosen-Bayer) for 1 hour. The protein array chips were subse-
quently washed in double-distilled water and dried prior to performing a dual
antibody immunoassay. Following secondary antibody incubation and a ﬁnal wash
step in BSA solution, the immunostained arrays were imaged using the ZeptoR-
EADERTM instrument (Zeptosens-Bayer). For each sub-array, ﬁve separate images
were acquired using different exposure times ranging from 0.5–10 s. Microarray
images representing the longest exposure without saturation of ﬂuorescent signal
detection were automatically selected for analysis using the ZeptoViewTM
3.1 software. A weighted linear ﬁt through the 4-fold concentration series was used
to calculate relative ﬂuorescence intensity (RFI) value for each sample replicate.
Local normalization of sample signal to the reference BSA grid was used to
compensate for any intra- or inter-array/chip variation. For the heatmap and bar
graph generation, all the data points were normalized for protein loading and
transformed to a linear value using R console statistical package, Microsoft Excel
and ImageJ.
TCGA. We downloaded publically available (miRNA and mRNA) pre-processed
data along with the relevant clinical information and ended up with complete
information for 428 patients (please refer to the “Data Availability” section for
further details). Survival analyses were performed in R (version 3.0.1) (http:///www.
r-project.org/) and the statistical signiﬁcance was deﬁned as a p-value less than
0.05. First, Univariate Cox proportional hazards model was ﬁtted to evaluate the
association between overall survival (OS) and co-variates including TRPA1 and
miRNA. This was based on the available expression levels and known important
clinical characteristics presented in cbio portal (age at diagnosis, stage, and
smoking status). TRPA1 and miRNAs were ﬁrst evaluated as continuous variables.
TRPA1 level and stage were statistically signiﬁcant factors, from the univariate Cox
proportional hazards models. They were included in the multivariable analysis of
OS in a model consisting of mRNA, miRNA and stage along with miRNAs found
statistically signiﬁcant at a level of fdr <0.1. Since among miRNAs, miR-142-3p
and miR-148-3p showed the highest signiﬁcance for this study, we continue the
description of the methods for these two miRNAs. Patients with high TRPA1 levels
and low miRNA expression levels had an increased estimated risk of death when
compared to the opposite trend (Supplementary Tables 1, 2 with the raw data
available in Supplementary Data 1 Excel Sheet). In order to visualize the survival
difference, we used the log-rank test to ﬁnd the point (cut-off) with the most
signiﬁcant (lowest p-value) split in high vs. low mRNA and miRNA level groups.
The Kaplan–Meier plots were generated for these cut-offs. The numbers of patients
at risk at different time points are presented at the bottom of the graph. The cut-off
to optimally separate the patients in high/low (min p-value) group was 0.34 for
TRPA1, 0.72 for miR-142-3p, and 0.28 for miR-148-3p. We then considered
adding second expression level. The ﬁxed cut-off for TRPA1 together with the ﬁxed
cut-off for miR-142-3p or miR-148-3p splits the cohort in four groups corre-
sponding to low/high TRPA1 and low/high miRNA expression. We contrasted the
two groups linked to a negative association: tumors with high levels of TRPA1 and
low levels of miRNA vs. tumors with low levels of TRPA1 and high levels of
miRNA. The difference in median survival time between the two groups contrasted
(38.3 months vs. median not reached for the pair TRPA1 and miR-142-3p and
36 months vs. 104 months for the pair TRPA1 and miR-148-3p) is signiﬁcantly
larger than the difference between the groups classiﬁed into high/low based on the
expression of TRPA1 or miRNA alone. We also generated survival curves for the 3
groups (the two groups linked to a negative association and the rest of the cases)
and veriﬁed the largest difference in survival time between the two groups
contrasted.
Data availability. The data supporting the ﬁndings of this study are available
within the paper and its supplementary information ﬁle. MicroRNA (miRNASeq)
and mRNA (RNASeqv2) pre-processed data were downloaded from the Cancer
Genome Atlas Project (TCGA) publicly available at Broad Institute (http://gdac.
broadinstitute.org/) for patients with LUAD. The clinical information was down-
loaded from cbioPortal (http://www.cbioportal.org/). Source data for the miRNA
analysis are provided as Supplementary Data 1. Additional relevant data are
available from the authors.
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